Paper42077458
Dose-response relationships of normal blood lipid levels in metabolic and endocrine diseases: mechanistic similarities, differences, and functional insights.
Hu X and 6 others. Front Endocrinol (Lausanne), 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Dose-response relationships of normal blood lipid levels in metabolic and endocrine diseases: mechanistic similarities, differences, and functional insights. Papers, record 42077458. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42077458
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dose-response relationships of normal blood lipid levels in metabolic and endocrine diseases: mechanistic similarities, differences, and functional insights.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endocrine System Diseases | Major topic |
| Lipids | Major topic |
| Metabolic Diseases | Major topic |
| Humans | |
| Lipid Metabolism | |
| Animals |
Source PubMed
References189
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23,504,260 | Hyperlipidemia modifies innate immune responses to lipopolysaccharide via the TLR-NF-κB signaling pathway. | Inflammation | 2013 | https://conductscience.org/library/papers/23504260 | PubMed |
| 2 | 22,740,706 | Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes. | J Clin Endocrinol Metab | 2012 | https://conductscience.org/library/papers/22740706 | PubMed |
| 3 | 33,937,267 | The Role of the Effects of Endoplasmic Reticulum Stress on NLRP3 Inflammasome in Diabetes. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/33937267 | PubMed |
| 4 | 39,062,066 | The Triglyceride/HDL Ratio as a Surrogate Biomarker for Insulin Resistance. | Biomedicines | 2024 | https://conductscience.org/library/papers/39062066 | PubMed |
| 5 | 18,588,961 | Dose response considerations in risk assessment--an overview of recent ILSI activities. | Toxicol Lett | 2008 | https://conductscience.org/library/papers/18588961 | PubMed |
| 6 | 33,828,530 | Signaling Pathways Involved in Nutrient Sensing Control in Cancer Stem Cells: An Overview. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/33828530 | PubMed |
| 7 | 34,402,692 | Potential role of anti-inflammatory HDL subclasses in metabolic unhealth/obesity. | Artif Cells Nanomed Biotechnol | 2021 | https://conductscience.org/library/papers/34402692 | PubMed |
| 8 | 38,078,592 | 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. | Diabetes Care | 2024 | https://conductscience.org/library/papers/38078592 | PubMed |
| 9 | 38,999,903 | Effects of Lipoproteins on Metabolic Health. | Nutrients | 2024 | https://conductscience.org/library/papers/38999903 | PubMed |
| 10 | 40,434,108 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. | Diabetes Care | 2025 | https://conductscience.org/library/papers/40434108 | PubMed |
| 11 | 38,636,099 | LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases. | J Clin Endocrinol Metab | 2025 | https://conductscience.org/library/papers/38636099 | PubMed |
| 12 | 25,452,768 | Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review). | Exp Ther Med | 2015 | https://conductscience.org/library/papers/25452768 | PubMed |
| 13 | 39,769,002 | The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769002 | PubMed |
| 14 | 30,251,697 | Type 2 diabetes - An autoinflammatory disease driven by metabolic stress. | Biochim Biophys Acta Mol Basis Dis | 2018 | https://conductscience.org/library/papers/30251697 | PubMed |
| 15 | 39,277,575 | Genome-wide discovery and integrative genomic characterization of insulin resistance loci using serum triglycerides to HDL-cholesterol ratio as a proxy. | Nat Commun | 2024 | https://conductscience.org/library/papers/39277575 | PubMed |
| 16 | 38,569,471 | Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity. | Cell Metab | 2024 | https://conductscience.org/library/papers/38569471 | PubMed |
| 17 | 37,484,947 | Sex differences in the non-linear association between BMI and LDL cholesterol in type 2 diabetes. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37484947 | PubMed |
| 18 | 39,808,821 | Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic. | Hepatology | 2026 | https://conductscience.org/library/papers/39808821 | PubMed |
| 19 | 30,006,369 | Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis. | J Lipid Res | 2018 | https://conductscience.org/library/papers/30006369 | PubMed |
| 20 | 40,917,348 | U-shaped relationship between the triglyceride glucose index and the risk of incident diabetes among MASLD adults: a retrospective cohort study. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/40917348 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42077458
GET https://conductscience.org/api/papers/v1/42077458/references?page=2